Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROBE: Belatacept Monotherapy in Kidney Transplant
NCT02939365Phase 4Withdrawn
- Sponsor
- University of California, San Francisco
- Start
- Feb 2019
- Primary completion
- Feb 2020
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 4, open-label, single-arm trial of belatacept in kidney transplant rejection, sponsored by University of California, San Francisco. Primary endpoints: Percent patients converted to belatacept monotherapy at 12 months and Percent patients safely converted to q8 week administration at 12 months. Planned start Feb 2019; status: withdrawn.
02
Drugs
belatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02939365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939365.